Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

Video

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Approved CLL agents, ibrutinib, a BTK-inhibitor and idelalisib, a PI3K-inhibitor, both target the b-cell receptor. There is another enzyme in that pathway known as SIK that can also be targeted, but there are currently no commercially available agents, says O’Brien.

There are several next-generation BTK- PI3K-, and SIK-inhibitors currently in clinical trials. The agent closest to potentially being approved is duvelisib, a PI3K-inhbiitor, says O’Brien. If its study is positive, it could potentially be available in the next two years, she says.

It will have to be determined if these next-generation agents are better than what is currently available. Agents that demonstrate improved efficacy and less toxicities are needed, says O’Brien.

Related Videos
Saad J. Kenderian, MB, CHB
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology